Leerink Swann assumed coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $22.00 target price on the biotechnology company’s stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2017 earnings at ($0.76) EPS, Q1 2018 earnings at ($0.64) EPS, Q2 2018 earnings at ($0.61) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.42) EPS, FY2018 earnings at ($2.13) EPS, FY2019 earnings at ($0.13) EPS, FY2020 earnings at $1.93 EPS, FY2021 earnings at $4.06 EPS and FY2022 earnings at $4.53 EPS.

Other equities analysts also recently issued reports about the company. Oppenheimer reiterated a buy rating and issued a $27.00 target price on shares of Heron Therapeutics in a research report on Friday, November 10th. Northland Securities assumed coverage on Heron Therapeutics in a research report on Wednesday, September 27th. They issued an outperform rating and a $40.00 target price for the company. Noble Financial restated a buy rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Cantor Fitzgerald restated a buy rating and set a $31.00 price objective on shares of Heron Therapeutics in a research report on Thursday, November 2nd. Finally, Mizuho assumed coverage on Heron Therapeutics in a research report on Tuesday, September 26th. They set a buy rating and a $28.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $28.82.

Heron Therapeutics (HRTX) opened at $18.55 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. The company has a market capitalization of $1,190.52, a PE ratio of -4.89 and a beta of 2.13. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $19.55.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities research analysts anticipate that Heron Therapeutics will post -3.39 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc grew its stake in Heron Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the period. Quantbot Technologies LP grew its stake in Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 12,024 shares during the period. Trexquant Investment LP acquired a new stake in Heron Therapeutics during the third quarter worth approximately $206,000. Jane Street Group LLC acquired a new stake in Heron Therapeutics during the third quarter worth approximately $223,000. Finally, HighTower Advisors LLC grew its stake in Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the period. Institutional investors own 98.78% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/heron-therapeutics-hrtx-now-covered-by-analysts-at-leerink-swann/1797383.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.